BioVenic converts animal pathogen genome and proteome data into evidence-ranked antigen and epitope shortlists. Our veterinary reverse vaccinology workflow integrates conservation, antigenicity, localization, immune-recognition, and expression-feasibility criteria to focus experimental resources on defensible vaccine candidates.
Emerging, variable, or poorly characterized animal pathogens can encode hundreds to thousands of possible antigens. Testing them without a transparent prioritization strategy consumes expression, assay, and animal-study capacity. A useful shortlist must explain why each candidate was retained, which assumptions drive its rank, and what evidence should be generated next.
BioVenic supports veterinary immunologists, vaccine R&D scientists, animal infectious disease researchers, academic PIs, and translational biologics teams. We build project-specific filters around pathogen biology, target species, vaccine format, available isolates, and downstream validation capacity, producing a decision-ready antigen or epitope set rather than an uncurated prediction list.
Scores are retained as separate evidence layers, allowing teams to inspect trade-offs rather than accept a single opaque composite value.
We assemble and normalize protein sets from supplied sequences or public accessions, review annotation quality, remove redundant records, and define the analysis universe. Multi-isolate projects can use ortholog or pangenome frameworks to distinguish core, accessory, and strain-restricted candidates.
Candidate proteins are evaluated for features relevant to immune exposure and vaccine use. Depending on the organism, these may include secretion signals, surface localization, transmembrane topology, adhesin-like features, domain context, and predicted antigenicity.
Conservation is assessed across relevant strains, lineages, geographic groups, or serotypes. Variant positions can be mapped to candidate epitopes. Host-homology and off-target similarity checks identify sequences that need removal, redesign, or further experimental scrutiny.
BioVenic can shortlist linear B-cell regions and MHC class I or II binding candidates, with allele selection aligned to the target species and available sequence information. Rankings can integrate binding, conservation, processing context, overlap, and practical peptide-design constraints.
We review sequence length, domain boundaries, transmembrane complexity, hydrophobicity, signal peptides, low-complexity regions, cysteine patterns, predicted solubility, and construct-truncation opportunities. A weighted model then separates selection criteria from caution flags. Documented thresholds and weights allow reranking when new isolates, results, or priorities emerge.
Tiered candidates, evidence scores, exclusion reasons, uncertainty flags, and recommended validation order.
The same numerical filter can have different biological meaning across viruses and bacteria. BioVenic adapts the evidence model to genome organization, antigen exposure, strain diversity, and the planned platform.
| Decision Layer | Bacterial Programs | Viral Programs | Decision Value |
|---|---|---|---|
| Sequence breadth | Core proteome, accessory genes, strain distribution | Structural proteins, lineage variation | Clarifies expected coverage |
| Exposure evidence | Surface localization, secretion, adhesin features | Virion exposure, entry role, domain context | Supports biological accessibility |
| Immune targeting | Protein antigens and conserved regions | Neutralization-relevant regions and T-cell targets | Focuses antigen or peptide testing |
| Development fit | Expression, domain boundaries, solubility | Platform compatibility and construct stability | Reduces downstream attrition |
Each stage includes a review point, allowing assumptions and shortlist size to be adjusted before resources are committed to the next analysis layer.
Confirm pathogen scope, target host, strain coverage, vaccine format, available sequences, exclusion criteria, and experimental throughput. Sequence provenance and annotation status are recorded.
Normalize identifiers, remove redundancy, review annotations, establish ortholog or isolate relationships, and define proteins or regions eligible for screening.
Evaluate conservation, localization, topology, antigenicity-related signals, functional context, host similarity, and sequence liabilities while preserving traceability.
Compare B-cell or T-cell regions using project-relevant parameters. Map conservation, allele binding, overlapping predictions, and variation to identify stable targets.
Assess construct boundaries, solubility-related features, hydrophobic segments, low-complexity regions, length, and platform compatibility. Alternative domains may be proposed.
Combine evidence using agreed weights, classify candidates into action tiers, document uncertainties, and recommend an order for expression, immune assays, and preclinical testing.
Outputs are organized for computational, immunology, protein-expression, and vaccine teams. The package can scale from a rapid feasibility assessment to a comparative multi-isolate animal pathogen antigen discovery program.
Filter results, evidence scores, ranks, and exclusion reasons.
Selected proteins, domains, or epitopes with identifiers.
Conservation maps, score profiles, and candidate tiers.
Parameters, database versions, thresholds, and assumptions.
Expression risks, construct suggestions, and liabilities.
Recommended experimental order and decision points.
The figure shows a bovine coronavirus workflow that begins with structural protein sequences and progresses through linear B-cell and T-cell epitope prediction, antigenicity and safety-related screening, structural modeling, molecular docking with TLR complexes, immune simulation, and in silico cloning. It demonstrates why epitope prioritization is strongest when several biological and development filters are integrated instead of relying on one prediction output.
The study provides a veterinary example of sequence retrieval, conservation review, MHC-oriented epitope mapping, physicochemical assessment, and construct evaluation before natural-host validation. BioVenic applies the same decision principle while tailoring databases, allele choices, thresholds, and feasibility checks to each pathogen and target species, producing a ranked experimental starting set with assumptions and uncertainties preserved.
Focused support for traceable, species-aware veterinary vaccine candidate decisions.
Host biology and relevant MHC information guide epitope selection.
Scores, weights, exclusions, and uncertainties remain fully reviewable.
Expression feasibility is considered before experimental candidate selection.
Deliverables connect computational evidence to a practical validation sequence.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.